If peptide therapy is recommended, we explain the regimen, evidence, and expected outcomes
No studies have examined whether BPC-157 use increases cancer risk, but the concern is biologically plausible
Gloves provide an additional layer of protection, preventing direct contact with the peptide and the mixing solution
Major retail pharmacies dispense finished commercial drugs
2) Phase 2 2 + cagrilintide 1.2 + semaglutide 1.2 = 15.6% , 2.2% HbA1c (vs semaglutide 2.4 : 5.1% / 1.8%)
What the Evidence Does NOT Show Because the marketing around these compounds is expansive, it is worth stating explicitly what the published record does not establish: It does not show that cagrilintide is superior, equal, or inferior to tirzepatide no head-to-head trial exists, so any ranking is cross-trial inference